|
|
|
LONG®R3IGF-I
 |
|
| Your Insulin Alternative |
|
Dedicated raw material manufactured specifically for industrial cell culture applications for supply continuity |
|
Regulatory compliant; animal-free and certified cGMP for consistency, compliance and reliability |
|
Proven cell science promotes cell proliferation, cell survival and culture longevity |
|
Security of supply backed by Novozymes, the world’s largest manufacturer of recombinant protein |
|
| |
Available as lyophilized powder and ready-to-use liquid formulation |
| |
| Product Number |
Description |
| 85580C |
LONG®R3IGF-I human
media grade, recombinant, expressed in Escherichia coli, lyophilized powder |
| 91590C |
Liquid LONG®R3IGF-I |
|
| |
| |
Sampling Information |
| |
Inquire about a sample of LONG®R3IGF-I. |
 |
| Proven Science for Better Cell Culture Performance |
| Used in the manufacture of several biopharmaceuticals approved by the FDA (United States), EMEA (Europe) and MHLW (Japan), with many more in late-phase clinical trials |
| |
|
|
Up to 200X more potent than insulin |
|
Maintains higher viability and extends culture duration |
|
Promotes cell proliferation |
|
Increases cell survival |
|
Eases transition to serum-free media |
|
Increases recombinant protein production |
|
Greater cell culture stability |
|
|
Learn more about how LONG®R3IGF-I can benefit your process development and biopharmaceutical production.
| LONG® is a registered trademark of Novozymes Biopharma AU. Covered by the following patents assigned to Novozymes Biopharma AU: US patents 5,330,971 and 5,164,370; European patents 429,586 and 346,429; Japanese patents 2,682,738 and 2,507,106; Australian patents 633,099 and 612,776; Canadian patents 2,033,176 and 1,341,204. |
|
|
